Hospitals and Healthcare Delivery in India
Backing or acquiring Indian hospitals: 100% automatic FDI, the deal, licences that don't travel, doctor lock-in, CCI, DPDP and the net-of-tax exit.
The foreign-investment gate is wide open. The work - and the value at risk - is the deal, the licences that do not travel, the doctors, and how the capital comes back out.
You already know why Indian healthcare delivery draws capital: a structural bed shortfall, a fast-formalising market, government and insurance cover widening the paying pool, and a medical-travel tailwind. We will not re-argue that case. The point worth internalising is a different one. In most Indian sectors the first question is whether foreign money is allowed in. In hospitals and healthcare services it simply is - 100% FDI on the automatic route, no prior government approval to own, build, acquire or back. So the question is not "can the money come in." It is "build, buy, or back" - and, the half most entry pages omit, "how does it come back out." This page is built around the deal and the exit, because for a foreign or UAE investor that is where the entire value is decided.
Almost every live story here is a transaction, not a greenfield. Private equity and strategic operators are consolidating - regional hospitals, single-specialty chains in eye care, IVF, dialysis, oncology and mother-and-child, and a still-fragmented diagnostics market - and the inbound foreign component sits inside that flow. So this is an M&A page first. It works through three layers that an open FDI gate does nothing to solve: the deal (valuation, structure, the licences that do not survive a slump sale, and doctor retention); the control and clearance layer (merger control, JV veto design, patient-data liability); and the exit and corridor layer (which routes a hospital actually exits to, and how the proceeds are taxed on the way to a UAE holding company). The deal mechanics hand off to our transaction-advisory team; the structuring and the corridor are where ATB does the work most competitors leave on the table.
At a glance
- 100% FDI, automatic route - the open gate is the easy part. The friction is the M&A, the operating licences, the merger-control filing and the exit, not the entry permission.
- It is a consolidation market. PE and strategic acquirers roll up regional hospitals, single-specialty chains and diagnostics labs; the roll-up is the default playbook (industry reporting, 2025).
- Licences do not travel. In a slump sale the clinical-establishment registration, accreditation and equipment licences generally have to be re-applied for and sequenced into completion - the asset can be bought but not lawfully run on day one if this is missed.
- Doctor retention is a commercial-design problem, not a covenant problem. Non-compete clauses on doctors have been held void (Madras High Court, in a widely reported decision); lock-in is built through economics, not restrictions.
- The exit is the first question a deal team asks. A hospital exits to a strategic acquirer, a PE secondary, a state-fund or platform buyer, or an IPO - and gains on shares of an Indian company remain taxable in India even under the India-UAE treaty, because the residence-only relief is for other assets, not Indian shares. Net-of-tax, not headline, is what the IRR turns on.
- Big platform deals are now caught by merger control on value, not just turnover. The CCI deal-value threshold (Rs 2,000 crore plus a "substantial business in India" test) has been in force since 10 September 2024.
- Patient data is a priced liability. The DPDP Rules 2025 are notified and commencing in stages; legacy non-consented patient records are a diligence item for any diagnostics or tech-enabled buyer.
The investment case, in one breath
The drivers, to prime rather than belabour: India runs at roughly 1.3 hospital beds per 1,000 people against a global average near 2.9, so organised capacity is absorbed quickly; Ayushman Bharat (PM-JAY) widens hospitalisation demand (Rs 5 lakh per family a year, extended from September 2024 to all citizens aged 70 and above), and insurance reform has enlarged the higher-margin insured pool; and the "Heal in India" medical-value-travel push adds an export tailwind. That is the runway. The rest of this page assumes you are persuaded and concentrates on what actually determines the return.
The market, in dated anchors only
Read all figures as dated industry estimates, never official data, and keep deal count separate from deal value. The single most authoritative provider-side compilation, Grant Thornton Bharat with AHPI (March 2025), recorded substantial private-equity and FDI inflows into hospitals across 2022-24 and several hundred analysed transactions, with specialty care (oncology, IVF, ophthalmology, dialysis) a standout. The most recent quarterly read, EY-Parthenon for Q2 FY26 (quarter to 30 September 2025), put announced healthcare deal value above INR 10,000 crore across hospitals, diagnostics and specialty care, with leading networks reporting double-digit ARPOB growth. Ownership has institutionalised - global funds hold controlling or large stakes across the leading platforms - and the exit leg is live, with at least one major chain having filed for a billion-dollar-plus IPO in early 2026 and multi-fund stake contests reported for marquee assets. The shape that matters is not any single number but the pattern: an active, capital-rich, consolidating market in which a foreign buyer competes on structuring and certainty, not just price. None of it guarantees a return.
Which healthcare-delivery entry are you?
The route is 100% automatic FDI in every row. What differs is the deal, the licence issue, and the clearance that most often derails it. The deal process and documents live at transaction advisory india inbound; the entity and FDI-route mechanics at india business setup.
| Route | Typical investor | Key legal / deal issue |
|---|---|---|
| Greenfield hospital (build new) | Strategic or UAE/GCC operator; sponsor | Licence sequencing (state clinical-establishment registration, AERB before installation, PCPNDT, biomedical waste, fire) plus land/lease, and a multi-year ramp to occupancy and ARPOB. Easy to enter, slow to mature. |
| Brownfield / acquired hospital | PE platform; strategic acquirer; consolidator | The deal: share vs slump sale, licence non-portability on change of control, the clinical-liability tail, related-party leakage, doctor retention, and CCI if the deal is large. |
| Single-specialty roll-up (IVF, eye care, dialysis, oncology, mother-and-child) | Single-specialty PE platform; specialty operator | Standardising fragmented clinics - clean title and a licence re-application per site, PCPNDT/AERB per machine, clinician lock-ins, and brand and protocol integration. Unit economics differ sharply by specialty (see below). |
| Diagnostics chain | Diagnostics roll-up sponsor; lab chain | NABL/state lab registration, PCPNDT for imaging, and patient-data liability under the DPDP regime - legacy non-consented records are a priced diligence item. |
| Day-care / clinic network | PE; specialty operator | How the state classifies and registers day-care units, and payor empanelment terms. |
| Homecare / tech-enabled care | VC/PE; digital-health operator | Telemedicine Practice Guidelines 2020, clinician registration, and DPDP - data is the asset and the risk. |
| PE / financial investor (minority or control) | Global/India PE fund | FEMA pricing on entry and exit, downstream-investment rules where investing through an Indian holdco/AIF, the SHA, and the exit route and its tax (mechanics at fema advisory and india structuring). |
| Strategic / operator JV | Foreign operator + Indian promoter / land owner | JV control mechanics (veto design, board control), brand/management/clinical-services fees (transfer pricing), the opco/propco split, and deadlock/exit. |
The deal: valuation, structure, diligence and the doctor problem
A hospital is valued on operating metrics, led by average revenue per occupied bed (ARPOB) - a single number that captures case mix, pricing power, payor profile and service complexity - alongside occupancy (hospitals carry heavy fixed costs, so margins step up sharply once occupancy crosses optimal thresholds), payor mix (cash and private insurance carry better economics than government-scheme tariffs), case mix (oncology, cardiac, neuro and transplant lift ARPOB over general medicine), and accreditation (NABH and NABL support empanelment, better rates and medical-travel flow, so they are value drivers, not compliance boxes). EBITDA multiples for Indian hospitals vary widely by tier and cycle and have at times been rich; treat any specific multiple as an illustrative, dated market figure rather than a benchmark, and assume private-market valuations sit below listed multiples once realistic growth is priced in. The drivers are durable; the numbers are not, and quoting last cycle's multiple adds no edge.
Structure turns on what the buyer wants to inherit - and on a licence problem most foreign buyers under-weight. A share deal acquires the company and with it everything: the licences (which generally need transfer or fresh registration on a change of control), litigation, the clinical-negligence tail, related-party contracts, the lease and the tax history. A business-transfer agreement or slump sale buys the undertaking as a going concern for a lump sum and ring-fences legacy liabilities - but the trade-off is decisive: operating licences and registrations are generally not portable. Clinical-establishment registration, NABH, NABL, PCPNDT, AERB, biomedical-waste authorisation and the pharmacy and blood-bank licences typically do not travel with the undertaking; the buyer must re-apply, and the timeline of those re-applications has to be sequenced into the completion mechanics - through conditions precedent, transition-services arrangements and, where lawful, run-on under the seller's permissions until the buyer's own come through. A deal that closes before the registrations are in hand can leave a buyer owning a hospital it cannot lawfully operate on day one. Because hospitals are real-estate-rich, deals are also frequently structured to separate the operating company from the property-owning entity (opco/propco), with a lease between them - which has a FEMA dimension addressed in the structuring section, and which interacts with stamp duty and how consideration is split. The general share-versus-slump-sale and transaction-document mechanics sit at transaction advisory india inbound and india structuring.
Diligence carries hospital-specific items beyond the usual. On clinical and liability: pending medical-negligence and consumer-forum claims, and records and consent practice. On regulatory: a valid clinical-establishment registration in the correct state; live NABH/NABL status; PCPNDT registration for every ultrasound and prenatal-diagnostic machine - an unregistered or non-compliant unit carries seizure and prosecution risk and is a frequent skeleton; AERB licences for X-ray, CT, cath-lab and radiotherapy; biomedical-waste authorisation with a live treatment-facility contract; fire and building approvals; the in-house pharmacy and blood-bank licences. On commercial: related-party leakage - promoter-linked referral, equipment, pharmacy and diagnostics supply contracts - which is common in promoter-run hospitals and is both a valuation and a transfer-pricing issue. On real estate: whether the hospital sits on leased, charitable-trust or government-allotted land, which can carry rent and free-treatment obligations that survive the deal. And, increasingly, on data: the patient-record estate and its consent history, now a quantifiable liability under the DPDP regime (below).
That brings the central integration risk into view: the doctors. A hospital's revenue is tied to senior consultants, many of them visiting or retainer practitioners rather than employees, who bring their own patient catchment; losing them after completion can hollow out the asset. The instinct is to lock them in with a non-compete - but Indian courts have held non-compete and non-solicitation clauses imposed on doctors to be void and opposed to public policy under Section 27 of the Indian Contract Act 1872, reasoning that doctors cannot be bound like ordinary employees (a Madras High Court decision, now widely reported and best treated as known law, though a High Court position and appealable). For a deal team the holding is not the news; the design consequence is. Retention has to be engineered as economics, not restriction: visiting-consultant and revenue-share agreements, affiliation and clinical-services arrangements, earn-outs and deferred consideration for promoter-doctors tied to clinician continuity rather than to a covenant, and - because conventional employee stock options rarely fit retainers - bespoke incentive instruments with their own dilution, governance and tax consequences. A term sheet that prices in a hard doctor non-compete is pricing in something that may not be enforceable as written; the value protection is the incentive architecture, not the restrictive clause.
Single-specialty economics: stop treating it as one bucket
"Single-specialty" is the most active roll-up theme in the market and the most carelessly described. What you are buying, and why it prices differently, varies completely by specialty - and the structuring follows the economics.
The point for an acquirer: the same "single-specialty roll-up" label hides an annuity, a cash-pay brand play, a capex-and-licence play and a throughput play, each with a different valuation basis, a different critical-path licence (PCPNDT for IVF and imaging, AERB for oncology) and a different retention exposure. Underwriting them identically is how roll-ups disappoint.
- Dialysis is an annuity: chronic patients return two to three times a week for years, revenue is recurring and predictable, ARPOB per session is low but utilisation and contract stickiness are high, and much of the volume is scheme- or insurer-funded. You are buying a base-load utilisation machine; the deal logic is unit count, payor contracts and cost per session, and the diligence is on equipment financing and partnership/PPP arrangements rather than star clinicians.
- IVF / fertility is cash-pay, cyclical and brand-led: largely out-of-pocket, demand sensitive to sentiment and disposable income, and driven by clinician reputation and outcome data. ARPOB per cycle is high but episodic. You are buying a brand and a clinician roster, so the central risk is the doctor-retention problem in its sharpest form, and PCPNDT compliance per centre is non-negotiable. Prices on brand and outcomes, not on beds.
- Oncology is capex-heavy and high-ARPOB: linear accelerators, cyclotrons and nuclear-medicine units make it the most AERB-laden specialty, with long approval lead times before equipment can even be installed. You are buying high-acuity revenue and a fixed-asset base; the deal turns on machine licensing, replacement capex and case-mix depth, and the diligence is heavy on AERB status and equipment vintage.
- Eye care is high-volume, standardised day-care: short-stay cataract and refractive procedures run on protocol and throughput, with strong operating leverage and limited inpatient infrastructure. You are buying a process and a network footprint; the value is in standardisation, surgeon productivity and catchment density.
- Mother-and-child sits between cash-pay and insured, brand-sensitive on the maternity side, with imaging that triggers PCPNDT and a referral network that needs protecting through transition. You are buying a catchment relationship and a brand.
Distressed and IBC as a deliberate acquisition channel
The Insolvency and Bankruptcy Code is a live, intentional way to acquire stressed hospital assets, not just a last resort. The illustrative anchor: the long-running insolvency of a large Mumbai hospital of roughly 1,500 beds, where the NCLT approved a resolution plan (order dated 19 January 2026; intimation late January, with wider reporting in February 2026) of about INR 456 crore by a resolution applicant with strategic equity support, carrying additional CIRP costs of around INR 205 crore and a separate municipal-dues settlement of around INR 223 crore, with secured creditors recovering roughly 40% and the asset to be run on a not-for-profit basis. The lesson generalises: distressed hospital assets can be attractively priced and acquired with a clean slate against admitted claims, but they come bundled with statutory-rent, municipal-liability and use-restriction conditions, the outcome is determined by the tribunal and the resolution process rather than assured, and the diligence is unusually heavy. For a foreign buyer with patience and structuring discipline, the IBC pipeline is a channel worth scanning deliberately.
Exit and repatriation: how the capital actually comes back
This is the half of an M&A page most competitors skip, and it is the first question a deal team asks: once the money is in and the asset has grown, how does a foreign or UAE investor get cash back, and what is the net-of-tax result? The general tax mechanics belong elsewhere on this site and we do not restate them: dividends are now taxed in the shareholder's hands with treaty-rate withholding, a buy-back was taxed as a deemed dividend in the shareholder's hands between October 2024 and March 2026, but the Finance Act 2026 restored capital-gains treatment for buy-backs completed from 1 April 2026 (with an additional buy-back tax at the company or promoter level), so a buy-back is once again broadly comparable to a share-sale exit rather than automatically the weaker option, and a sale of unlisted shares produces capital gains, all set out at india tax, with FEMA entry and exit pricing (the floor-and-ceiling on price, certified by a merchant banker or chartered accountant) at fema advisory. Two things are healthcare-specific and worth the words: which routes a hospital actually exits to, and how the India-UAE treaty really reads on exit gains.
The healthcare exit-route map. A hospital or specialty platform realises value through a recognisable menu, and the entry structure is designed for the likely route:
The route in view drives the entry design - a platform built for a trade sale is shaped differently from one built to IPO, and the SHA, drag/tag mechanics and doctor-incentive architecture are calibrated to it.
The India-UAE treaty on exit gains - read it correctly. This is the point most online summaries get wrong, and getting it right is the corridor advantage. Under Article 13 of the India-UAE DTAA, gains from the alienation of shares of a company resident in India may be taxed in India (the source-state right is retained). The often-quoted "residence-only, effectively nil" treatment is the residual clause for other property, not the clause for Indian-company shares - so a UAE investor should not assume the gain on selling an Indian hospital company escapes Indian tax, and the loose "0% on exit" claims circulating online are an over-claim. Any reliance on the residual clause must be grounded in the asset actually sold and stress-tested against the principal-purpose test (India adopted the PPT through the MLI, which covers this treaty; CBDT guidance issued January 2025), so a UAE holding structure needs genuine substance, not just a Tax Residency Certificate.
Exit is, in short, a net-of-tax exercise modelled at entry, not after the asset has grown - the general tax and FEMA-pricing mechanics sit at india tax and fema advisory, and future restructuring at transaction advisory india inbound.
- Strategic acquirer. A larger hospital group or operator buys for beds, geography, specialty depth or brand - the most common trade exit for a regional hospital or a single-specialty chain, and the route a roll-up is usually built to deliver.
- PE secondary. One financial sponsor sells a built-up platform to another - a frequent mid-life exit in this market, where a first fund institutionalises a fragmented asset and a larger fund takes it to the next scale.
- State-fund or platform buyer. State investment funds, global infrastructure-style investors and large healthcare platforms acquire marquee or controlling stakes in leading networks - the deep-pocket end of the market that prices scarcity.
- IPO. A scaled network lists on the Indian market - a live route, with at least one major chain having filed a billion-dollar-plus IPO in early 2026 - giving the sponsor a phased exit and public currency for further roll-up.
FEMA and structuring: the healthcare-specific points
The general FEMA mechanics are owned elsewhere and only primed here: capital instruments and entry/exit pricing under the NDI Rules 2019, FC-GPR / FC-TRS reporting, the downstream-investment rules where a foreign investor comes in through an Indian holdco or AIF, and the outbound ODI leg under the Overseas Investment Rules 2022 are all at fema advisory, india business setup and india structuring. Two points are healthcare-specific and decide whether a hospital deal holds together.
The "incidental property" rule. FEMA prohibits foreign investment in a "real-estate business", but hospital construction is expressly outside that prohibition and an operating company may hold or lease the property necessary for, or incidental to, its own healthcare business. In the opco/propco split, the lease and documentation have to make the property holding read as incidental to running the hospital, not as a property play - that characterisation is where the FEMA position lives or dies.
FEMA exit pricing, as it bites on a hospital. The general floor-and-ceiling is at fema advisory; the healthcare point is that a strategic premium or a scarcity-priced state-fund bid still has to clear the fair-value test on the way out, so the exit valuation must be defensible on the operating metrics (ARPOB, occupancy, accreditation, case mix), not merely agreed.
A worked deal-map (anonymised and illustrative)
To convert this from explainer to reference, here is a single anonymised, caveated map of how the pieces fit on a typical corridor deal. It is illustrative only; every fact is deal-specific and nothing here is advice.
The deal: a UAE family office acquires a single-specialty chain - say IVF, or eye-care - operating across two or three Indian states.
1. Entity and capital. The investor holds the Indian opco through a UAE holding company (corridor and treaty reasons, below), investing as FDI on the automatic route in equity instruments under the NDI Rules, with entry pricing at or above fair value and FC-GPR filed (mechanics at india business setup and fema advisory). If a roll-up is intended through an Indian holdco, the downstream-investment rules and Form DI are built in from the first bolt-on.
2. Structure choice. Because licences do not travel, the parties weigh a share deal (inherit the company and its licences, ring-fence by warranty and indemnity) against a slump sale (clean liabilities, but re-apply for every registration). If slump sale, the per-state clinical-establishment re-applications and per-site PCPNDT (and, for oncology, per-machine AERB) registrations become conditions precedent and transition items - the deal cannot complete into a chain that cannot lawfully operate.
3. Real estate. Clinics are split opco/propco where the chain owns premises, with leases drafted so the property holding is incidental to the healthcare business for FEMA, and stamp duty modelled on the property transfers.
4. Doctors. The founder-clinicians and key consultants are retained through revenue-share, affiliation and earn-out structures tied to continuity - not non-competes, which would be unenforceable - with deferred consideration and bespoke incentives for the promoter-doctors, and an upside above a threshold on exit to align them with the platform's eventual sale.
5. Control. The SHA sets reserved matters and affirmative-vote rights, board composition, and the founders' protections and obligations (tag, drag, anti-embarrassment), calibrated to whether the family office is taking control or a significant minority (the general JV mechanics sit at india structuring).
6. Clearance. If the platform value crosses the CCI deal-value threshold and the target has substantial Indian business, the combination is notified to the CCI (or run through the green channel if there is genuinely no overlap); large roll-ups test this at each material bolt-on.
7. Data. The patient-record estate is diligenced for DPDP consent history; legacy non-consented records are priced as a liability and a remediation plan is agreed.
8. Exit. The investor models the net-of-tax return across the realistic exit routes - a strategic trade sale, a PE secondary, a state-fund/platform buyer or an IPO - with dividends (treaty-rate withholding) and a future buy-back (capital-gains-treated again from 1 April 2026 after the Finance Act 2026 reversal, subject to the new company-level buy-back tax) weighed against a share-sale exit, India's source-state right on Indian shares preserved under the treaty, the PPT satisfied by genuine substance, and FEMA exit pricing observed.
That single map - entity, per-state licence re-applications, per-site PCPNDT/AERB, doctor lock-in by economics, opco/propco with FEMA pricing, CCI, DPDP, and a net-of-tax exit - is the spine of a corridor healthcare deal. The figures and the route are chosen on the facts; the sequence is general.
Merger control: when a roll-up or mega-deal becomes notifiable
For years, Indian merger control turned only on the parties' assets and turnover, so high-value deals over targets with thin Indian revenue could escape review. That changed. Under the Competition (Amendment) Act 2023 and the Combination Regulations 2024 (in force from 10 September 2024), a transaction is notifiable to the CCI if its deal value exceeds INR 2,000 crore and the target has "substantial business operations in India." For a non-digital target, "substantial business in India" is met broadly where its India turnover in the preceding year exceeds 10% of its global turnover and is more than INR 500 crore (confirm the current thresholds and tests at deal time). The consequence for healthcare: a platform roll-up or a marquee hospital acquisition can now be caught on value even where the standard asset/turnover tests are not met, and the de-minimis (small-target) exemption does not rescue a deal that is otherwise caught by the deal-value threshold. Where parties genuinely have no horizontal, vertical or complementary overlap, the green channel offers deemed approval on filing - useful for a financial investor entering a clean space, but unavailable to a strategic consolidator with existing healthcare assets, and revocable if the no-overlap declaration is wrong. Merger-control analysis now belongs in the deal plan from the term-sheet stage, not as a closing afterthought; the filing itself is run with our transaction team (transaction advisory india inbound).
JV control with Indian promoters: the doctor-promoter dynamic
Many corridor deals are joint ventures with an Indian promoter or land-owner who stays in, and control is a matter of drafting, not shareholding percentage. The generic toolkit - reserved matters and affirmative-vote rights, board control versus protected minority, tag, drag, rights of first offer/refusal, lock-ins, anti-embarrassment and the warranty/indemnity package - is owned by india structuring and transaction advisory india inbound and not restated here. What is healthcare-specific is the promoter-doctor dynamic: the promoter is frequently a founder-clinician whose own catchment and reputation are part of what is being bought, so the package has to keep that clinician engaged, not merely tied down - the reserved-matters list extends to senior clinical hires, change of clinical scope and related-party referral/supply contracts (the leakage risk). Because the non-compete the law will not enforce cannot do the work, retention runs on economics: the promoter-doctor is commonly given a share of exit proceeds above a value threshold, aligning them with growing and selling the platform and substituting for the void covenant - and that upside has to be drafted as one package with the deferred-consideration, revenue-share and earn-out retention terms from the deal section, not in a separate silo. Get this wrong and the formal vetoes hold control of an asset whose founding clinician has disengaged and whose catchment is walking.
The DPDP Act for hospitals: data as a priced liability
Healthcare runs on the most sensitive category of personal data, and India now has a statute that puts a price on getting it wrong. The Digital Personal Data Protection Act 2023, operationalised by the DPDP Rules 2025 (notified 13-14 November 2025 and commencing in stages, with several obligations phased in over the following 12-18 months - confirm which provisions are live at deal time), makes a hospital, lab or care platform a data fiduciary with real duties: a consent architecture (notice, purpose limitation and a lawful basis for processing patient data), security safeguards, breach notification, and - for significant fiduciaries - additional governance. The enforcement teeth are material: penalties can run up to around INR 250 crore for serious failures such as inadequate security safeguards leading to a breach. For an acquirer this is not abstract compliance - it is a diligence and pricing item:
DPDP turns patient data from a soft compliance topic into a quantifiable deal liability. The cross-border-transfer structuring links to india structuring and india tax; the diligence is hospital-specific and sits in the transaction.
- Legacy non-consented patient data is the headline liability. Years of records collected without DPDP-grade consent are an inherited exposure for the buyer; the consent history of the existing patient estate has to be diligenced and a remediation plan priced in, particularly for diagnostics chains and tech-enabled-care platforms whose data is also their core asset.
- Cross-border transfer of patient data (to a UAE holding company's systems, an offshore cloud, or a global analytics function) must fit the DPDP transfer regime - relevant to any tech-enabled or diagnostics buyer that intends to centralise data.
- A diagnostics or digital-health buyer must price DPDP into the model, because for these businesses the data is the value: a data-handling failure is not just a fine, it is a hit to the asset itself.
Foreign-clinician recognition: the real bottleneck on scaling a specialty centre
For an inbound operator intending to bring in or rely on foreign-qualified doctors, the binding constraint is rarely capital or licence - it is clinician recognition. A foreign medical graduate generally cannot practise in India without clearing the screening exam and registering. As at June 2026 the operative screening test is the Foreign Medical Graduate Examination (FMGE); the National Exit Test (NExT) that is to replace it has been deferred (with rollout pushed to 2028-29 and the position to be confirmed), so the FMGE remains the live route. Beyond the exam, a foreign graduate must obtain provisional registration with a State Medical Council, complete a compulsory one-year rotating internship in an approved institution, and then secure permanent registration with the NMC or the State Medical Council before practising independently - a realistic time-to-licence measured in many months to over a year from arrival, even for an experienced clinician. The implication for a foreign operator is concrete: a specialty centre cannot be staffed quickly by importing doctors, so the scaling plan has to be built on Indian-registered clinicians - which loops straight back to the retention problem, because those are exactly the consultants a non-compete cannot bind. Clinician supply, not the FDI gate, is often the true rate limiter on building out a specialty network.
Provider licensing: the operating layer
Owning a hospital is not the same as being licensed to run it, and the licensing layer is state-specific and sequential. At its centre is the Clinical Establishments (Registration and Regulation) Act 2010 - a central law on registration and minimum standards - but health is a State subject, so it applies only in the states and union territories that have adopted it (broadly nineteen states and union territories), while several large states, including the NCT of Delhi, Maharashtra, Karnataka, Tamil Nadu and West Bengal, run their own nursing-home or clinical-establishment Acts. The practical takeaway for a chain is simply that registration is a patchwork, the operative law has to be confirmed facility by facility, and that confirmation is a real diligence and integration cost - not a list to memorise.
Around that sit the accreditations and equipment approvals. NABH (hospitals) and NABL (labs) accreditation are voluntary but commercially close to essential, underpinning empanelment, scheme and insurer rates and medical-travel eligibility. PCPNDT registration is required for every ultrasound and prenatal-diagnostic unit, with strict record-keeping. AERB licensing governs radiology and radiotherapy equipment (X-ray, CT, cath-lab, linear accelerators, nuclear medicine), and the process must begin before installation - the single most common scheduling trap on an oncology or imaging build. Biomedical-waste authorisation under the Bio-Medical Waste Management Rules 2016, with a common-treatment-facility contract, must be in place before opening. An in-house pharmacy needs a drug licence under the Drugs and Cosmetics Act 1940 and a registered pharmacist (the product and registration side of medicines belongs to our pharma page). Telemedicine and homecare run under the Telemedicine Practice Guidelines 2020. Layered on are state fire and building approvals and, where relevant, a blood-bank licence. The sensible sequence: entity and FDI, then land, building and fire, then state clinical-establishment registration, then equipment licences (AERB, PCPNDT), then biomedical waste, pharmacy and blood bank, then NABH/NABL, then payor empanelment. Each outcome is determined by the relevant authority on the facts; none is guaranteed.
FDI, land and the land-border rule
The FDI route is settled and not re-taught here: hospitals and healthcare services, including diagnostics and pathology, are open to 100% FDI on the automatic route, with the capital-instrument, pricing and RBI-reporting mechanics at india business setup and fema advisory and the deal mechanics at transaction advisory india inbound. (This differs from drug and device manufacturing, where a brownfield acquisition faces a 74% automatic ceiling and conditions - the territory of our pharma page.) The land point - foreign ownership of the premises permitted as incidental to the healthcare business, and the opco/propco care it demands - is covered in the FEMA section above. The point worth stating here is land-border capital.
Where a beneficial owner is from a country sharing a land border with India (the rule most often engaged by Chinese capital), the blanket prior-approval requirement of Press Note 3 (2020) was liberalised by Press Note 2 of 2026 (Union Cabinet approval 10 March 2026; issued by DPIIT 15 March 2026): a land-border beneficial owner of up to 10%, with no control, may now invest under the automatic route subject to sectoral caps, with DPIIT reporting in a prescribed format (reported as a 60-day window); above 10%, or where there is control, prior government approval continues to apply, and a later change of beneficial ownership into the restricted category also needs approval. This is recent and still being operationalised, so treat it as dated and confirm before relying. In every case the automatic route gets the money in; it does not assure the operating licences, which are decided on the facts.
Tax and structuring: the healthcare-specific angles
The general tax depth - GST, transfer pricing, withholding, POEM, the treaty and the exit-tax mechanics - is owned by india tax and only primed here. Three points carry a healthcare twist:
- Company versus charitable trust. An investable hospital is almost always a private limited company, clean for FDI, a PE round and an exit. The charitable forms (trust, society or Section 8 company) can claim income-tax exemption but constrain profit distribution and rarely fit a sponsor's return expectations - so the charitable structure is something to identify in diligence (often tied to subsidised land and free-treatment obligations), not a vehicle a foreign investor adopts.
- GST, in one line: core healthcare services are exempt, but non-ICU room rent above Rs 5,000 per day is taxable (the whole rent), ICU rent is exempt and purely cosmetic procedures are taxable - confirm the GST Council's current thresholds at india tax.
- Transfer pricing. Intra-group management, brand-royalty and clinical-services fees to a UAE holdco or between related Indian entities must be at arm's length - the healthcare flag is that royalty and management fees on a hospital platform are a known scrutiny area, so the benefit test and documentation are built in, not bolted on (mechanics at india tax).
The India-UAE corridor
For a UAE or GCC operator, sponsor or family office, the corridor is the centre of gravity of a hospital deal. The general corridor architecture is owned in full by india uae business structuring and only primed here: a UAE holdco actually managed from India risks POEM and deemed Indian residence (so board substance must be real), treaty access on dividends needs a valid TRC and a structure that survives the PPT, and any leg sending Indian capital out runs under ODI - with the tax mechanics at india tax and the FEMA leg at fema advisory.
The healthcare-specific framing is the one to hold onto: when a hospital group or family office holds an Indian hospital company through a UAE vehicle, the point that most often goes wrong is the exit-gains reading - Article 13 preserves India's source-state right on gains from Indian-company shares, so a hospital sold out of a UAE holdco is not treaty-exempt (see the exit section). The corridor advantage on a hospital is real but specific, and it is destroyed by the over-claiming the loose online summaries invite. The corridor structuring sits at india uae business structuring.
Incoming opportunities and capital-recycling routes
A few wider, fact-grounded angles for an operator or sponsor thinking beyond a single acquisition:
- Real-estate monetisation - watch, do not assume. Hospitals are property-heavy, and the opco/propco split already separates the bricks from the operations - which raises the question of recycling the property through a REIT or InvIT. As at mid-2026 there is no listed healthcare-specific REIT in India; the listed REIT market is office, retail and (via InvITs) infrastructure. But the regime is moving - SEBI reclassified REIT units as equity instruments from 1 January 2026, and a small-and-medium REIT (SM REIT) framework opens lower-value asset pools - so hospital real-estate monetisation via a REIT/InvIT is a plausible future capital-recycling and partial-exit route to design toward, not a precedent to rely on today. Frame it as optionality in the propco, confirmed against the regime at the time.
- Medical value travel as an investable tailwind. The "Heal in India" push - dedicated medical and AYUSH visa categories, streamlined e-medical visas, a medical-value-travel portal and proposed regional medical hubs - is a real, policy-backed demand stream for accredited, internationally oriented hospitals. Market-size estimates vary widely by source (one puts the sector near US$8.7bn in 2025 rising toward US$16bn by 2030), so cite the direction, not a single figure - but for an asset with NABH accreditation and the right specialties, export demand is a genuine part of the thesis.
- State incentives - the carrot, not just the land-liability stick. Charitable-land obligations are a risk, but several states court private hospital investment: the central framework encourages states to ease land allotment, fast-track clearances and offer viability-gap funding of up to around 40% of project cost for hospitals serving PM-JAY in under-served cities, and individual state industrial and health policies offer stamp-duty reimbursement, capital subsidy and land concessions for qualifying hospital projects (terms vary by state and bed/investment thresholds). For a greenfield or Tier 2/3 expansion, mapping the available state incentives is part of the underwriting.
- The distressed pipeline. As above, the IBC channel is a deliberate, scannable source of brownfield assets at resolution-process prices, with conditions.
- GIFT City - relevant for the fund, not the hospital. For a fund or holding vehicle backing Indian healthcare, the GIFT City IFSC offers an onshore-yet-offshore platform - AIFs under the IFSCA Fund Management Regulations 2025, with tax concessions on non-resident income and pass-through features - that can be relevant to how a healthcare-focused fund is domiciled and how foreign and NRI capital is pooled. It is a fund-structuring consideration, not something that changes the hospital's own licensing or FDI position; raise it where the investor is building a vehicle, not a single asset.
Indicative timelines (order-of-magnitude, heavily caveated)
Approvals run in parallel, outcomes are authority-determined, and these are planning ranges only - confirm for the specific state, asset and authority:
The critical path on a hospital deal is usually set by the slowest of the licence re-applications, AERB, and (if applicable) the charitable and CCI approvals - which is why the structure and the completion mechanics are designed around them.
- AERB (radiology/radiotherapy): must start before equipment installation; lead time can run from weeks to several months depending on equipment class - the binding constraint on an oncology or imaging build.
- Clinical-establishment registration on change of control / re-application after a slump sale: state-dependent; plan in weeks to months, and sequence into completion rather than assuming day-one continuity.
- Charitable-trust / Charity Commissioner approvals (where a trust-owned or trust-land asset is involved): can be slow and unpredictable, often the long pole on a charitable-structure deal.
- CCI clearance (where the deal is notifiable): a defined statutory review with a substantially shortened outer timeline under the 2024 regime, but to be built into the deal calendar from the term sheet; the green channel gives near-immediate deemed approval where there is genuinely no overlap.
- NABH / NABL accreditation: a multi-month process post-readiness, valid for a fixed term with surveillance - a value driver to schedule, not a gating permission.
Where this goes wrong
- Reading the open FDI gate as the whole story. 100% automatic gets the money in; it does nothing for the licences, the merger-control filing, the data liability or the exit - which is where the time and the value go.
- Letting licences fall through a slump sale. A business transfer ring-fences liabilities but usually does not carry the registrations; if the re-applications are not sequenced into completion, the asset can be bought but not lawfully run.
- Assuming a doctor non-compete will hold. It will not; a deal that locks promoter-doctors in by covenant rather than by economics can lose the very clinicians whose patients were being bought.
- Missing PCPNDT and AERB skeletons. Unregistered ultrasound or radiology equipment carries seizure and prosecution risk and surfaces in diligence, not after; AERB started after installation is a scheduling failure.
- Mispricing patient data. Legacy non-consented records and cross-border transfer are real DPDP liabilities, especially for diagnostics and tech-enabled buyers where the data is the asset.
- Forgetting merger control on value. A large platform roll-up or marquee deal can be notifiable on the deal-value threshold even where the old turnover tests are not met.
- Over-claiming the treaty on exit. Assuming a UAE holdco makes Indian share-sale gains tax-free misreads Article 13; India keeps its source-state right on Indian shares, and the PPT tests the structure.
- Running a UAE holdco from India. Day-to-day control from India can create POEM and deemed Indian residence, undoing the intended treaty and holding position.
How ATB Corporate helps
ATB Corporate advises foreign and cross-border investors on entering, building, acquiring and backing Indian healthcare-delivery businesses - hospitals, diagnostics, single-specialty platforms, day-care and homecare. We frame the build-buy-or-back decision and design the deal around the things the open FDI gate does not solve: the structure (share versus slump sale, the licences that do not travel, the opco/propco split and its FEMA incidental-property and exit-pricing points), the doctor-retention architecture the law now makes a commercial rather than a contractual exercise, JV control and the promoter-doctor dynamic, merger-control analysis, and patient-data liability - working the transaction alongside our transaction-advisory team. We map the provider-licensing path and the indicative critical-path timelines, and we build the exit and corridor from the start: which routes the asset realistically exits to, the UAE holding structure with its POEM, TRC and principal-purpose-test discipline, and the net-of-tax modelling - with the general FEMA, tax and corridor mechanics drawn from our fema advisory, india tax and india uae business structuring teams - that decides the real return. We do not operate hospitals, and we do not promise a particular FDI, licensing or tax outcome - those are determined by the relevant authorities on the facts - but we structure the entry, the deal and the exit so the position is sound and the risks are seen before, not after, completion.
Hospitals & Healthcare Delivery — Answered
Hospitals and healthcare services, including diagnostics and pathology, are permitted up to 100% under the automatic route, so no prior government approval is needed to own or build. The standard FEMA requirements apply - capital instruments and pricing under the Non-Debt Instruments Rules 2019 and FC-GPR reporting to the RBI. The constraints a foreign investor meets are generally not the FDI cap but the transaction, the state-level provider licences, merger control on larger deals and the exit.
A hospital or specialty platform usually realises value through one of four routes: a sale to a strategic acquirer (a larger hospital group buying for beds, geography or specialty depth); a PE secondary (one financial sponsor selling a built-up platform to another); a sale to a state investment fund or large healthcare platform for a marquee or controlling stake; or an IPO on the Indian market. The entry structure - the holding vehicle, the shareholders' agreement and the drag/tag mechanics - is designed for the likely route, and the proceeds are then taxed under the general dividend, buy-back and capital-gains rules, which is why the after-tax outcome is best modelled at entry.
A sale of shares produces capital gains taxable in India; for a non-resident, long-term gains on unlisted shares are taxed at 12.5% (for transfers on or after 23 July 2024) without indexation, plus surcharge and cess. Under the India-UAE treaty, India generally retains the right to tax gains on shares of an Indian-resident company - the residence-only treatment in the treaty applies to other property, not to Indian-company shares - so a UAE seller should not assume the gain is exempt, and any treaty position must satisfy the principal-purpose test.
In addition to the long-standing asset and turnover thresholds, a transaction is notifiable under the deal-value threshold introduced by the Competition (Amendment) Act 2023 and the Combination Regulations 2024 (in force from 10 September 2024) where the deal value exceeds INR 2,000 crore and the target has substantial business operations in India. A large platform roll-up or marquee hospital deal can therefore be caught on value, and the green channel offers deemed approval only where there is genuinely no horizontal, vertical or complementary overlap.
Indian courts have held that they are not - the Madras High Court has held non-compete and non-solicitation clauses imposed on doctors to be void and opposed to public policy under Section 27 of the Indian Contract Act 1872, on the basis that doctors cannot be bound like ordinary employees. As a High Court position it remains appealable, but the practical effect is settled in deal design: doctor retention has to be built through revenue-share, affiliation, earn-out and deferred-consideration structures rather than restrictive covenants.
A share deal acquires the company and with it all of its history, including licences (which generally need transfer or fresh registration on a change of control), litigation and tax. A slump sale buys the undertaking as a going concern and ring-fences legacy liabilities, but the operating registrations usually do not travel, so the buyer must re-apply for clinical-establishment registration, accreditation and the equipment and waste licences - and those re-applications have to be sequenced into completion, because a hospital cannot be lawfully run without them.
Yes. A hospital, lab or care platform is a data fiduciary under the DPDP Act 2023, operationalised by the DPDP Rules 2025 (notified in November 2025 and commencing in stages), with duties on consent, security and breach notification and penalties that can reach around INR 250 crore for serious failures. For an acquirer, legacy patient records collected without adequate consent are an inherited liability to diligence and price, and cross-border transfer of patient data must fit the DPDP transfer regime - a particular concern for diagnostics and tech-enabled-care buyers whose data is the core asset.
Not without recognition. A foreign medical graduate must clear the screening examination - currently the Foreign Medical Graduate Examination, since the National Exit Test that is to replace it has been deferred - obtain provisional registration with a State Medical Council, complete a compulsory one-year rotating internship in an approved institution, and then secure permanent registration with the NMC or State Medical Council before practising independently. Realistic time-to-licence runs to many months or more, which is why a specialty network usually has to be staffed with Indian-registered clinicians rather than imported doctors.
Registration is state-specific. The Clinical Establishments (Registration and Regulation) Act 2010 is a central law adopted by around nineteen states and union territories, while several large states - including the NCT of Delhi, Maharashtra, Karnataka, Tamil Nadu and West Bengal - run their own nursing-home or clinical-establishment Acts. A chain operating across states therefore meets a patchwork of regimes, and the operative law has to be confirmed for each facility's state.
FEMA prohibits foreign investment in a real-estate business, but the construction of hospitals is outside that prohibition and an operating company may acquire, hold or lease the immovable property necessary for, or incidental to, its own healthcare business. The structuring care is to ensure the property holding reads as incidental to running the hospital rather than as a property play; deals are often structured with the operating company separated from a property-owning entity under a lease, and any leg that sends Indian capital abroad runs under the Overseas Investment Rules 2022.
It is among India's more active M&A markets. Industry compilations - for example Grant Thornton Bharat with AHPI (March 2025) and EY-Parthenon's quarterly data into FY26 - record substantial private-equity, FDI and strategic activity, with consolidation through roll-ups of regional hospitals, single-specialty chains and diagnostics labs, and a live exit leg of IPOs and secondary sales. These figures are dated industry estimates rather than official data, and deal count and deal value should be read separately.
A UAE or GCC investor commonly holds the Indian hospital company through a UAE structure, which adds a tax-residence and treaty layer. A UAE entity managed from India risks Place of Effective Management in India and deemed Indian residence; treaty access on dividends and fees needs a UAE Tax Residency Certificate, genuine beneficial ownership and satisfaction of the principal-purpose test; gains on Indian shares generally remain taxable in India under the treaty; and any outbound leg runs under the Overseas Investment Rules 2022. The corridor is planned with the India structure and the exit, not separately.
In Indian hospitals the FDI gate is open, so value turns on the deal: licences that do not survive a slump sale, doctor lock-in that a non-compete cannot hold, the CCI deal-value test, and the net-of-tax exit.
Licensing, approvals and any tax treatment are decided by the authorities on the facts. Talk to our team when you are ready.
Get in touch